ClinicalTrials.gg
RecruitingNCT07151976TAPOSUpdated Feb 5, 2026

Thrombus Aspiration and Pathology and OCT Study

An observational study in Acute Coronary Syndrome, sponsored by Fujita Health University. Recruiting at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Fujita Health University · Observational

How we know

From the registry’s dates

  • Started Jul 2016; still recruiting 10 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Acute Coronary Syndrome with a site in Japan — 3 open to participants now, 7 under way, 1 of them phase 3. Acute Coronary Syndrome · Japan.

Started
2016
with 2 others
Observational
8 of 33
2 open now
Registered
28th of 33
by date

Among the 33 studies in Acute Coronary Syndrome with a site in Japan, this one is one of 3 that started in 2016, is one of 8 observational ones, and was the 28th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

3 of the 33 studies in Acute Coronary Syndrome with a site in Japan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Acute Coronary Syndrome with a site in Japan, or all of them as a file.
02

Study summary

Most acute coronary syndromes (ACS) are caused by plaque complications triggering thrombotic events in the culprit plaques. Plaque complications include plaque rupture (Ruptured Fibrous Cap-RFC) with exposure of highly thrombogenic substrate to the flow and plaque erosion (Intact Fibrous Cap-IFC) a condition characterized by endothelial/intimal damage occurring over non-ruptured plaques. Far less commonly (\<5%), calcified nodules (CN) may trigger acute coronary thrombosis. Plaque rupture accounts for 75% of fatal AMI in autopsy series, while erosion is found in about 25% of cases. These proportions have been supported by in vivo invasive studies (OCT) and OCT-pathology correlation studies. However, it remains unclear whether OCT findings consistently align with in vivo pathology-based evidence of RFC in ACS. Guidelines addressing treatments of ACS unanimously indicate percutaneous coronary intervention (PCI) to restore the coronary flow. Pre-PCI thrombus aspiration is not currently indicated by most guidelines, with the exception of cases with very high thrombus burden. The samples retrieved from thrombus aspiration can be suitable for pathology investigation and aim to evaluate the presence of plaque components in the context of the thrombotic material, a finding that demonstrates plaque rupture as the substrate for the acute coronary event. These studies are uniquely qualified to provide information on the correct OCT-based interpretation of plaque complications in ACS and require OCT imaging quality suitable to classify RFC, IFC, and CN.

Therefore, a prospective OCT-pathology study was designed using the pre-PCI aspirated material from patients with high thrombus burden, to explore the contribution of pathology study in OCT-based classification of plaque complications.

Read the detailed description

AIM Primary aim The present study aims to assess whether the composition of thrombus-aspirated material differs in samples retrieved from patients with OCT-described plaque rupture, erosion, or calcified nodules. In particular, the specific aim is to assess the presence of plaque components (atheromatous material, consisting of cholesterol clefts, foam cells, iron-loaded macrophages, cap fragments, and calcifications) in plaques described at OCT as RFC, IFC, and CN. The working hypothesis is that the pre-PCI aspirated material from plaque rupture should contain plaque components, while aspirated material from plaque erosion, should only contain thrombotic material. The pathology study was planned to be performed blindly to imaging data, and report independent descriptors of the pathology features.

Secondary aims

  1. A secondary aim addresses pathophysiology mechanisms, potentially related to features promoting plaque rupture. Given the proposed major role of macrophages in the context of plaque inflammation commonly observed in vulnerable plaque prone to rupture, we aimed to investigate the presence of M1 (pro-inflammatory, pro-rupture effect) and M2 (anti-inflammatory, anti-rupture effect) macrophages in samples containing plaque material.
  2. A further secondary aim is the assessment of short- and long-term outcomes in patients with OCT-diagnosed plaque complications, as identified by imaging and confirmed by pathology.

SAMPLE SIZE Due to the unprecedented similar in vivo studies and the non-routine possibility of performing pre-PCI thrombus aspiration according to guidelines, it was not possible to precisely calculate the sample size.

Based on the probability of plaque rupture in ACS (75% in consecutive ACS) and erosion (25% in consecutive series), a minimum number of 100 cases was considered necessary for the study scope.

PATIENT RECRUITMENT The study is conducted at the Fujita Health University Hospital, Okazaki Medical Center, and Nagoya First Red Cross Hospital. The study was approved by local ethics committees (HM 16019) and was carried out according to the guidelines of the Declaration of Helsinki. Written informed consent was obtained from all patients before index PCI.

PATHOLOGICAL ANALYSIS The pathologic study was planned to be performed at the IRCCS, Policlinico San Matteo, Pavia, Italy, where samples had to be blindly analyzed after routinely processing for histopathology.

Pathological plaque rupture (PATHO-PR) was defined as the presence within the retrieved samples of atheromatous material, consisting of cholesterol clefts, foam cells, iron-loaded macrophages, cap fragments/fibrous tissue, and calcifications.

Serial sections for each case were stained (H\&E, MOVAT, Perls', Von Kossa). The immuno-characterization of the macrophage populations was performed by immunostaining sample sections with antibodies to the pan-macrophage CD68, and M1 (CD80, CD86, IL-6) and M2 (CD163, CD206, TGF-β) polarized macrophage.

Samples with plaque material were classified as RFC-derived, while thrombus-only samples were unsuitable for plaque analysis.

CLINICAL EVALUATION Clinical outcomes were planned at 100 days and 5 years. Major adverse cardiac events (MACE) included cardiac death, non-fatal ACS, ischemia-driven revascularization, cardiogenic shock, and heart failure requiring hospitalization.

03

Conditions studied

  • Acute Coronary Syndrome
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Between July 2016 and December 2024, 200 consecutive patients with ACS having large angiographic thrombus burden who assumed to have a merit of thrombotic aspiration and who consented to OCT guided PCI procedures with athero-thrombotic aspiration were enrolled in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with ACS showing ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) are studied.
  2. Only native coronary artery lesions are included in the study.
  3. Optical coherence tomography (OCT) was performed prospectively to compare OCT culprit lesions characteristics with histological analysis of athero-thrombotic aspirated material of the culprit lesion. For this purpose, only lesions with both athero-thrombotic aspirated material and OCT observations are included in the study.
  4. All patients provided written for the index procedure, follow-up, and anonymous data management.

Exclusion criteria

Exclusion Criteria:

  1. Patients are excluded from the study when they had cardiogenic shock and to anticoagulation and anti- therapy.
  2. Lesions located in tortuous vessels, in ostial segment and in the left main stem are excluded from the study due to the difficulty in performing high-quality intracoronary imaging.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples without dna

Interventions

  • DevicePCI

    PCI with athero-thrombotic aspiration and subsequent pathological analysis: Pathologic Characteristics of Athero-Thrombotic AsPirated Material of OCT-Verified Culprit Lesion in Acute Coronary Syndrome

06

What researchers measure

Primary outcomes

  1. Concordance between pathology based and optical coherence tomography (OCT) verified diagnosis of plaque rupture

    TAPOS is an observational prospective study that aims to investigate the concordance between pathology versus OCT-verified features of plaque rupture in patients with STEMI and NSTEMI undergoing PCI and athero-thombus aspiration from the culprit coronary plaque. Pathology measured features are assessed in the aspirated material retrieved from the target coronary plaque and include the presence of foam or iron-loaded macrophages, cholesterol clefts, fragments of fibrous tissue, and calcifications assessed as single or combined features. OCT-based features of plaque include coronary thrombi, fibrous cap discontinuity or plaque ulceration (contraposed to non-ruptured, continuous fibrous cap with over-imposed thrombus).

    Time frame: From 2016 to 2027

Secondary outcomes

  1. Concordance between pathology-based and optical coherence tomography (OCT) verified detection of macrophages

    TAPOS is an observational prospective study that investigates the concordance between pathology vs. OCT-verified features of plaque rupture in patients with STEMI and NSTEMI undergoing PCI and thrombus aspiration from the culprit coronary plaque. Pathology measured features assessed in the aspirated material retrieved from the target coronary plaque include the presence of foam- or iron-loaded macrophages, cholesterol clefts, fragments of fibrous tissue, and calcifications, as single or combined feature/s. OCT-based features of plaque rupture include fibrous cap discontinuity, plaque ulceration (contraposed to non-ruptured, continuous fibrous cap with over-imposed thrombus). In addition, TAPOS investigates the correlation between the OCT-based detection of macrophages (signal-rich, distinct, or confluent punctate regions that exceed the intensity of background speckle noise) and the pathology observation of macrophages in the thrombus-aspirated material retrieved from each lesion.

    Time frame: From 2016 to 2027

  2. The incidence rate of major adverse cardiac events (MACE)

    Major adverse cardiac and cerebral events (MACE): the composite of cardiac death, non-fetal MI, and unstable angina requiring PCI or CABG

    Time frame: From 2016 to 2027

  3. The incidence rate of major adverse cardiac and cerebrovascular events (MACCE)

    Major adverse cardiac and cerebral events (MACCE): the composite of cardiac death, non-fetal MI, and unstable angina requiring PCI or CABG, and stroke

    Time frame: From 2016 to 2027

  4. The incidence rate of major adverse cardiac and fatal events

    Major adverse cardiac and cerebral events: the composite of all-cause death, non-fetal MI, and unstable angina requiring PCI or CABG

    Time frame: From 2016 to 2027

  5. The incidence rate of major cardiac, cerebrovascular, and fatal events

    Major adverse cardiac and cerebral events: the composite of all-cause death, non-fetal MI, and unstable angina requiring PCI or CABG, and stroke

    Time frame: From 2016 to 2027

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2016 (actual). Primary completion is estimated for Dec 2027, 137 months after the start.

Of 243 non-industry observational studies under Acute Coronary Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 137 months is above that.

Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2022
First posted
Sep 3, 2025
StartActual
Jul 1, 2016
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07151976
Lead sponsor
Fujita Health University
Responsible party
Yukio Ozaki (Clinical Professor, Fujita Health University) — Principal investigator
First posted
Sep 3, 2025
Start date
Jul 1, 2016
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 5, 2026

Study contacts

Yukio Ozaki, MD, PhD
Contact
ozakiyuk@fujita-hu.ac.jp
+1 9492996512
Reina Ozaki, MD
Contact
yukio.ozaki7@gmail.com
+1 9492996512
YUKIO OZAKI, MD, PhD
principal investigator · Fujita Health University, Aichi, Japan
Eloisa Arbustini, MD
study chair · IRCCS Foundation Policlinico San Matteo, Pavia, Italy

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion